CADILAHC:NSE-Cadila Healthcare Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 577.35

Change

-21.40 (-3.57)%

Market Cap

INR 614.53B

Volume

4.68M

Avg Analyst Target

INR 587.60 (+1.78%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company offers products in the therapeutic areas of pain management, neurology, dermatology, rare diseases, specialty oncology, gastroenterology, and liver diseases. It also provides consumer wellness products, such as Sugar Free and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. Cadila Healthcare Limited was founded in 1952 and is headquartered in Ahmedabad, India.

Company Website : http://www.zyduscadila.com

Address : Zydus Corporate Park, Ahmedabad, India, 382481

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.61

52 Week High : 673.70

52 Week Low : 358.00

200 Day Moving Average : 538.62

50 Day Moving Average : 635.07

Shares Held By Insiders : 75.01%

Shares Held by Institutions : 12.87%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-0.50 (-0.07%)

 INR1,651.46B 56.88 31.75
DIVISLAB:NSE Divi's Laboratories Limited

+99.20 (+2.07%)

 INR1,271.97B 64.10 43.96
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-111.60 (-2.30%)

 INR802.95B 46.73 22.27
AUROPHARMA:NSE Aurobindo Pharma Limited

+9.70 (+1.07%)

 INR530.51B 9.95 6.61
LUPIN:NSE Lupin Limited

-8.65 (-0.78%)

 INR504.63B 41.60 20.35
ALKEM:NSE Alkem Laboratories Limited

-13.35 (-0.39%)

 INR404.61B 25.53 18.73
LAURUSLABS:NSE Laurus Labs Limited

-13.55 (-2.14%)

 INR339.24B 34.58 23.16
IPCALAB:NSE Ipca Laboratories Limited

-57.75 (-2.58%)

 INR283.87B 24.80 17.25
AJANTPHARM:NSE Ajanta Pharma Limited

+83.20 (+3.70%)

 INR194.58B 29.95 17.96
NATCOPHARM:NSE NATCO Pharma Limited

-22.25 (-2.14%)

 INR189.43B 43.00 26.32

ETFs Containing CADILAHC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.68% 44% F 33% F
Dividend Return 0.73% 65% D 36% F
Total Return 21.42% 46% F 34% F
Trailing 12 Months  
Capital Gain 60.04% 38% F 35% F
Dividend Return 0.97% 72% C- 37% F
Total Return 61.01% 38% F 34% F
Trailing 5 Years  
Capital Gain 57.36% 49% F 58% F
Dividend Return 3.73% 78% C+ 47% F
Total Return 61.09% 51% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 11.08% 39% F 56% F
Dividend Return 0.61% 64% D 65% D
Total Return 11.69% 38% F 56% F
Risk Return Profile  
Volatility (Standard Deviation) 42.32% 64% D 63% D
Risk Adjusted Return 27.62% 41% F 61% D-
Market Capitalization 614.53B 95% A 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.73 49% F 42% F
Price/Book Ratio 4.77 43% F 22% F
Price / Cash Flow Ratio 18.66 50% F 28% F
EV/EBITDA 20.70 37% F 34% F
Management Effectiveness  
Return on Equity 16.40% 54% F 75% C
Return on Invested Capital 14.09% 60% D- 80% B-
Return on Assets 6.90% 50% F 77% C+
Debt to Equity Ratio 4.69% 47% F 65% D
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.61 66% D 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector